SPPH Spencer Pharmaceutical Inc (CE)

Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH), announced today the addition of Dr. Michael D. Buschmann to the Corporation's Scientific Advisory Board.

Dr. Buschmann has joined its Scientific Advisory Board and will also assess new scientific opportunities for the Company.

Dr. Buschmann received a B. Engineering Physics from the University of Saskatchewan in 1984, and a Ph.D. in Medical Engineering and Medical Physics from the Division of Health Sciences and Technology at the Massachusetts Institute of Technology and Harvard University in 1992. His postdoctoral training was then completed at the University of Bern in Switzerland in 1994. Since 1994, he has established a multidisciplinary research program as Professor of Biomedical Engineering and Chemical Engineering at Ecole Polytechnique. The program focuses on the use of biomaterials for tissue repair and the development of polymer-based gene and drug delivery systems for Diabetes, Cancer and Inflammatory diseases (http://www.polymtl.ca/tissue/). Dr. Buschmann has published 90 articles, 205 conference proceedings and 13 patented or patent pending inventions.

He is currently the Director of the FRSQ Group in Biomedical Science and Technology and has received the Innovator Prize from the Quebec Association for Industrial Research (ADRIQ), the Melville Medal from the American Society of Mechanical Engineers (ASME), and the Award of Merit from the Canadian Arthritis Network of Centers of Excellence.

"Dr Buschmann will advise and plan product development strategies and assess additional technologies and research that Spencer is interested in licensing into the company. Discussions will also continue in this sense in the coming weeks," said Dr Max Arella, CEO of Spencer Pharmaceutical Inc. In addition "we are confident that the experience, dedication and the vision of Dr Buschmann will bring exciting new opportunities into our company adding tremendous value for our shareholders," further stated Dr Arella.

About Spencer Pharmaceutical Inc.

Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

Important Information

About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.

Contact: Dr. Max Arella President Spencer Pharmaceutical Inc. 1+(617) 973-5017